

1 **TITLE:** Development and validation of a near-comprehensive RxNorm valueset of opioid
2 medications

3
4 **AUTHORS:** Michael Wasz, MPH^{1,2}, Prabhu RV Shankar, MD, MS⁴, Elizabeth Sprouse, MPH²,
5 Lyndsey Kirchner, MPH.⁵, Matthew H. Garber³, James Jones, MPhil³, Kenneth D. Mandl, MD,
6 MPH^{3,6}, Andy McMurry Ph.D.^{3,6}

7
8 **AFFILIATIONS:** ¹Emory University Rollins School of Public Health, 1518 Clifton Rd., Atlanta,
9 GA 30322

10 ²Double Lantern Informatics, 3456 Landen Pine Ct., Atlanta, GA 30305

11 ³Computational Health Informatics Program, Boston Children's Hospital, 300 Longwood Ave.,
12 Boston, MA 02115

13 ⁴Division of Health Informatics, University of California Davis Health, 4610 X Street,
14 Sacramento, CA 95817

15 ⁵CDC Foundation, 600 Peachtree Street NE, Suite 100, Atlanta GA 30308

16 ⁶ Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of
17 America

18
19 **CORRESPONDING AUTHOR:** Michael Wasz, 331-238-2030, mgwasz@gmail.com

20
21 **MAIN TEXT WORD COUNT:** 2116

22 **ABSTRACT WORD COUNT:** 184

23
24 **KEYWORDS:** Analgesics, Opioid; RxNorm; Drug Classification; Electronic Health Records;
25 Public Health Informatics

26 **ABSTRACT**

27

28 **Objective:** Develop a near-comprehensive opioid medications valueset for population measures
29 of opioid related treatments and outcomes. The opioid valueset should be free, open source, and
30 conform to the RxNorm standard federally mandated in every US-certified electronic health
31 record.

32

33 **Materials and Methods:** Cumulus opioid valueset was manually curated by the authors and
34 expanded using computer assisted curation. Opioid classifier rules were developed to select
35 opioid RxNorm concepts with known opioid receptor interactions, ingredients, keywords, and
36 drug product formulations. Twelve publicly available valuesets were used to develop and
37 validate the Cumulus opioid valueset. Validation accuracy was measured against a corpus of
38 opioid medication orders and non-opioid pain relievers.

39

40 **Results:** Cumulus opioid valueset recall was >99.9% when measured against opioid prescription
41 RxNorm codes from UC Davis Health and Brigham and Women's Hospital. Cumulus opioid
42 valueset was 100% specific compared to three valuesets of non-opioid pain relievers.

43

44 **Discussion and Conclusion:** To the authors' knowledge, Cumulus opioid valueset is the largest
45 publicly available valueset of opioid medications (8,926 RxNorm concepts). The intended use of
46 this opioid valueset is for population health measures of opioid medications and related patient
47 outcomes.

48

49 INTRODUCTION

50 Opioid-based analgesia is the most commonly used treatment in postoperative pain management,
51 with more than 95% of surgical patients receiving opioids during hospitalization[1,2]. This
52 accounts to roughly 55 million patients in the United States each year. While many patients
53 treated with opioids recover well, others experience opioid related adverse events[2] or develop
54 opioid use disorder(OUD) [3,4]. To measure the frequency of opioid prescriptions[5,6] and
55 opioid related outcomes[7], a comprehensive vocabulary[8] of opioid medication concepts are
56 needed.

57 Electronic health records (EHR) contain longitudinal patient history[9–11], enabling
58 measurements of patient status before, during, and after medication orders containing opioids,
59 [12,13]. By analyzing the frequency of patient care trajectories involving opioid medications, it
60 should be possible to decipher which care trajectories most commonly lead to better or worse
61 outcomes. EHR data is a valuable resource to measure outcomes of opioid use disorder
62 treatments such as naloxone and buprenorphine. At the time of this study, there are at least 30
63 opioid valuesets listed by the US national library of medicine (NLM)[8]. However, it remains
64 unclear which combination of opioid valuesets should be selected to maximize sensitivity and
65 specificity in opioid medication studies.

66 The primary objective of this study is to develop a near comprehensive list of opioid
67 concepts referencing RxNorm[14]. RxNorm is the federally mandated standard drug vocabulary
68 in the United States Core Data for Interoperability (USCDI)[11]. RxNorm contains precise drug
69 type information, including brand names, generic names[15], medication strength, prescribable
70 drug names[16], and relationships[17,18] to drugs across thirteen common medical vocabularies.
71 The secondary objective of this study is to enable “push button population health” [9]

72 measurement of opioid prescriptions and outcomes at national scale by adopting 21st Century
73 Cures Act [19] mandated health data USCDI standards[11].

74 This study reports the Cumulus opioid valueset code[20] and data[21], freely available
75 under the Apache-2.0 open source license. The Cumulus opioid valueset is published on
76 VSAC[22].

77 **METHODS**

78 The Cumulus opioid valueset was developed using published sources of opioids[23–30], expert
79 manual curation, and computer assisted curation (**Figure 1**). Published valuesets were
80 downloaded from the Value Set Authority Center (VSAC)[8]. Authors manually reviewed each
81 opioid entry from an opioid medication valueset[29] using the Unified Medical Language
82 System (UMLS) and Bioportal[31]. Each opioid concept was expanded to a larger valueset of
83 opioid concepts having one or more opioid ingredients. Authors then manually curated a list of
84 opioid ingredients, opioid keywords, and opioid classification rules for computer assisted
85 curation. The medication reference terminology[32–34] (MED-RT) was used to automatically
86 select all RxNorm concepts with known opioid receptor interactions[35,36]. Published opioid
87 valuesets[23–30] were processed using opioid ingredients, opioid keywords, and opioid
88 classification rules. The valueset aggregation of RxNorm concepts selected for opioid
89 ingredients, opioid keywords, opioid receptor interactions, and opioid classifier rules were used
90 to compile the Cumulus opioid valueset. Three VSAC non-opioid valuesets[37–39] were
91 analyzed to provide examples of medications that do not include opioids. Non-opioid valuesets
92 were used to test if non-opioid concepts were incorrectly included in the Cumulus opioid
93 valueset. Lastly, sources of opioid prescriptions were analyzed to validate real world use of

94 Cumulus opioid valueset in two medical centers.

95 **Expert Manual Curation**

96 The authors manually reviewed each opioid RxNorm concept from an opioid medications
97 valueset[29] and verified each concept included an opioid ingredient in Bioportal. Each
98 ingredient was then expanded using UMLS to include all RxNorm relationships[40] for all drug
99 product formulations. In addition to ingredient-level curation, opioid keywords were curated to
100 search for additional opioid medications. Common opioid-related terms, including both generic
101 and brand names, were curated and refined iteratively to reduce false positives. The cumulus
102 opioid keyword list was appended with a list of published VSAC valueset of opioid medication
103 keywords[30].

104 **Computer Assisted Curation**

105 Computer assisted curation was developed to expedite expert manual curation. Two
106 computerized methods were developed: an opioid classifier and an MED-RT medication
107 hierarchy of opioid receptor interactions. The opioid classifier rules were curated to select related
108 opioid medications having similar opioid keywords, brand names, generic names, and multi-
109 ingredient formulations by leveraging relationships such as "ingredient of" and "tradename of."
110 Additional rules were curated to disambiguate drug products with multiple ingredients such as
111 cold medicines containing opioids. In total, the opioid classifier included keywords, ingredient-
112 level relationships, and drug product formulations. The supplementary material contains the
113 complete opioid classifier ruleset for each pair of RxNorm concepts, term types, and relationship
114 attributes.

115 MED-RT was used to recursively include all RxNorm concepts in a hierarchy of opioid
116 receptor interactions. MED-RT concepts were selected matching the keyword "opioid". MED-

117 RT provides a hierarchy of medication classes[32], namely mechanism of action (MoA),
118 established pharmacologic class (EPC), and physiologic effects (PE). **Figure 2** illustrates the
119 MED-RT partial hierarchy of Mu (μ) and Kappa (κ) opioid receptor interactions. Delta (δ) and
120 nociceptin/orphanin FQ (NOP) receptors[41] are not included in the MED-RT hierarchy as there
121 are currently no prescribable opioid medications for delta (δ) and NOP receptors.

122 **Accuracy Measurements**

123 Sensitivity and specificity were measured for the Cumulus opioid valueset against nine VSAC
124 opioid valuesets[22–29,41] and three VSAC non-opioid valuesets[37–39]. **Figure 3** illustrates
125 accuracy measurements. Sensitivity (recall) was measured as the percentage of VSAC opioid
126 concepts recalled using the Cumulus opioid valueset, using formula true positive (TP) divided by
127 the sum of TP plus false negative (FN) [i.e. $TP / (TP + FN)$]. Specificity (true negative rate) was
128 measured using formula true negative (TN) divided by the sum of TN plus false positive (FP)
129 [i.e. $TN / (TN+FP)$]. True positives were defined as opioid concepts in a VSAC opioid valueset.
130 True negatives were defined as opioid concepts in a VSAC non-opioid valueset. False positives
131 were defined as opioid concepts present in both the Cumulus opioid valueset and an VSAC non-
132 opioid valueset. False negatives were defined as opioid concepts present in a VSAC opioid
133 valueset that were not present in the Cumulus opioid valueset. Truth conflicts exist when the
134 same RxNorm concepts is present in both a VSAC opioid and VSAC non-opioid valueset.
135 VSAC truth conflicts were resolved by authors (MGW, AJM, PRVS) to confirm ground truth
136 labeling.

137 **RESULTS**

138 Cumulus opioid valueset resulted in 8,926 unique opioid RxNorm concepts (**Figure 4**). To the
139 authors' knowledge, this is the largest publicly available opioid valueset conforming to standards
140 federally mandated in every US-certified electronic health record system.

141 Manual curation of 349 opioid medications[29] using UMLS/BioPortal yielded an
142 expanded list of 2,007 RxNorm concepts. Opioid classifier rules were then used to select an
143 additional set of 3,861 related concepts. MED-RT hierarchy included 1,834 concepts with a
144 known opioid receptor interaction[35], which were then related to an additional 3,766 concepts
145 using the opioid classifier rules. Opioid keywords were used to select 1,864 concepts from
146 published VSAC opioid valuesets, which were then expanded to include 1,520 additional
147 concepts. In total, 8,926 unique RxNorm concepts were selected using manual curation, opioid
148 receptor interactions, opioid keywords, and opioid classifier rules of related RxNorm concepts.

149 **Validation**

150 Cumulus opioid valueset was tested against multiple opioid and non-opioid valuesets, yielding
151 >99.9% sensitivity and 100% specificity. Cumulus recalled 1,193 of 1,994 unique RxNorm
152 concepts. Of these, Cumulus recalled all 228 concepts for opioid oral tablets and patches from
153 Brigham and Women's Hospital[42]. Cumulus recalled 1007 of 1137 concepts for opioids in the
154 UC Davis Health set of opioid prescriptions. Upon manual review, only 1 of the 130 concepts
155 missing opioid concepts was determined to be a prescribable opioid medication. The single truth
156 conflict was due to the UC Davis Epic EHR medications grouper inadvertently including
157 individual ingredients such as aspirin, ibuprofen, and guaifenesin that are commonly prescribed
158 with codeine.

159 Cumulus opioid valueset specificity was 100% compared to three published VSAC
160 valuesets for non-opioids[37–39]. None of the 3877 non-opioid RXCUIs were present in the
161 Cumulus opioid valueset. Additional validation was performed against 2048 non-opioid concepts
162 in a MED-RT hierarchy containing RxNorm concepts for classes: NSAID, barbiturate, and/or
163 benzodiazepine. Confirmed by manual review, the Cumulus opioid valueset contained zero false
164 positives from any non-opioid valueset[22].

165 VSAC validation rules were applied to the set of 8,926 RxNorm concepts resulting in
166 4,123 active concepts and 4,803 inactive concepts. Both active and inactive concepts are
167 provided to readers to enable historical analysis of opioid prescriptions since the start of the
168 opioid crisis.

169

170 **DISCUSSION**

171 To the authors' knowledge, this study presents the largest publicly available valueset of opioid
172 medications using the RxNorm standard. The intended use of the Cumulus opioid valueset is to
173 quickly measure opioid population health statistics across multiple healthcare organizations in
174 parallel[9]. Cumulus is designed for use with US core standards for interoperability(USCDI) [43]
175 with over 100 data elements[44] relevant to opioid studies, especially medications[45],
176 conditions[46,47], vital signs[48], laboratory results[49], diagnostic reports[50],
177 observations[51], clinical notes[52], and demographics[53] across a wide range of encounter
178 settings[54]. When used with the USCDI data, Cumulus opioid valueset may be used to measure
179 frequency of opioid prescriptions[55], trajectories of opioid use[56], treatment of opioid use
180 disorders[57,58], and other opioid related population health statistics.

181 There were several limitations in this study. The Cumulus opioid valueset includes
182 RxNorm opioid medication prescribed by a healthcare professional. Opioids acquired
183 outside[59] of the healthcare system cannot be measured using prescriptions alone[60]. It was
184 beyond the scope of this study to evaluate case definitions of substance use disorders using
185 diagnosis concepts[61] and laboratory results[62]. Despite best efforts, it should be expected that
186 not all cases of opioid use will be counted. The unregulated opioid supply frequently changes
187 ingredient mixtures and chemical structures thus limiting detection using standardized toxicology
188 screens. To estimate the true opioid use prevalence from the apparent opioid use prevalence[63],
189 clinical notes[52] could be reviewed for a small sample of the population to adjust prevalence
190 estimates.

191 **LEGENDS OF FIGURES**

192 **Figure 1 caption: Methods to curate and validate the opioid Cumulus valueset.** Published
193 sources were human expert curated and expanded using computer assisted curation. The
194 Cumulus opioid valueset contains the aggregation from these curated sources. Validation is
195 measured against opioid medication orders and non-opioid VSAC valuesets.

196 **Alt text:** Flowchart showing the process for curating and validating the Cumulus opioid valueset.
197 Published sources, such as opioid receptor interactions and VSAC valuesets, undergo human
198 expert curation and are expanded through computer-assisted curation using tools like MED-RT
199 and BioPortal.

200
201 **Figure 2 caption: Example RxNorm medications in the MED-RT hierarchy of opioid**
202 **receptor interactions.** Opioid receptors hierarchically link RxNorm ingredients and RxNorm
203 prescribable products. Shaded boxes denote MED-RT hierarchical concepts for the established
204 pharmacologic class of opioid receptor interactions. Arrows denote direction of the hierarchical
205 relationships. Unshaded boxes denote RxNorm medications. Bold denotes RxNorm ingredient
206 concepts. Boxes on the bottom of the hierarchy provide examples of generic names, brand
207 names, dose form, and strength. “Buprenorphine 8 MG / Naloxone 2 MG” illustrates how
208 multiple ingredients can be combined in a single product.

209 **Alt text:** Hierarchical diagram illustrating the MED-RT hierarchy for opioid receptor
210 interactions. The diagram branches into opioid agonists and antagonists, which further divide
211 into full, partial, competitive, and non-competitive subtypes. Examples of RxNorm medications
212 include Oxycodone (a full opioid agonist for the Mu receptor) and Narcan (a competitive opioid

213 antagonist). Additional medications such as Buprenorphine 8 MG / Naloxone 2 MG are shown
214 as products with combined ingredients.

215

216 **Figure 3 caption: Accuracy of ground truth labels against the Cumulus and VSAC**

217 **valuesets.** True positives denote RXCUIs present in both Cumulus opioids and VSAC opioids.

218 False negatives denote RXCUIs present only in VSAC opioids valuesets. False positive RXCUIs

219 denote Cumulus opioids also present in VSAC non-opioids. True negative denotes RXCUIs

220 present only in VSAC non-opioids. Truth conflict denotes RXCUIs present in both VSAC

221 opioids and non-opioids.

222 **Alt text:** Venn diagram illustrating the accuracy of Cumulus and VSAC valuesets. True positives

223 are represented by the overlap between Cumulus opioids and VSAC opioids. False negatives

224 refer to RXCUIs only present in VSAC opioids, while false positives denote RXCUIs present in

225 Cumulus opioids but also found in VSAC non-opioids. True negatives represent RXCUIs only in

226 VSAC non-opioids. A central section shows truth conflict, where RXCUIs exist in both VSAC

227 opioids and non-opioids.

228

229 **Figure 4 caption: Cumulus opioid valueset curation and validation.** Published sources of

230 opioid receptor interactions, opioid keywords, and opioid medications are curated. Human expert

231 curation included UMLS/BioPortal and curation of common opioid keywords. Cumulus assisted

232 curation of opioid receptor interactions and published VSAC opioid valuesets. Cumulus opioid

233 valueset resulted in 8,926 unique RxNorm concepts. Validation was performed against hospital

234 opioid medication orders and valuesets of non-opioid pain-relievers.

235 **Alt text:** Flowchart detailing the process of curating and validating the Cumulus opioid valueset.
236 Human expert curation incorporates opioid receptor interactions, keywords, and concepts from
237 UMLS/BioPortal. The process expands through computer-assisted curation, adding concepts
238 from the MED-RT hierarchy and various VSAC valuesets. The final aggregation yields 8,926
239 unique RxNorm concepts, validated against opioid medication orders (99.9% sensitivity) and
240 non-opioid valuesets (100% specificity).
241

242 **DECLARATION OF INTERESTS:** Elizabeth Sprouse is the founder of Double Lantern
243 Informatics, a for-profit consulting firm, and served as a consultant to the CDC Foundation
244 during this project. The author has no significant conflicts of interest that would affect the
245 integrity of the research. All other authors declare no conflicts of interest.

246 **DATA SHARING:** Data and code are freely available under the Apache-2.0 license. Code for
247 building the Cumulus opioid valueset is available at [https://github.com/smart-on-fhir/cumulus-](https://github.com/smart-on-fhir/cumulus-library-opioid-valueset)
248 [library-opioid-valueset](https://github.com/smart-on-fhir/cumulus-library-opioid-valueset). Supplementary data is available at [https://github.com/smart-on-](https://github.com/smart-on-fhir/cumulus-library-opioid-valueset-supplement)
249 [fhir/cumulus-library-opioid-valueset-supplement](https://github.com/smart-on-fhir/cumulus-library-opioid-valueset-supplement) .

250 **ACKNOWLEDGMENTS:** Authors thank the UC Davis pharmacy and informatics teams with
251 special thanks to Eugene Kang and Momeema Ali.

252 **FUNDING:** This work was supported by the Office of the National Coordinator for Health
253 Information Technology contract numbers 90AX0031/01-00, 90AX0022/01-00, and
254 90AX0040/01-00; Centers for Disease Control and Prevention of the United States Department
255 of Health and Human Services (HHS) as part of a financial assistance award, Strengthened
256 Community Partnerships for More Holistic Approaches to Interoperability totaling \$1,985,178
257 (The contents are those of the author(s) and do not necessarily represent the official views of, nor
258 an endorsement, by the CDC Foundation, CDC/HHS, or the U.S. Government); The National
259 Center for Advancing Translational Sciences/National Institutes of Health Cooperative
260 Agreements U01TR002623 and U01TR002997; National Association of Chronic Disease
261 Directors/Centers for Disease Control and Prevention Grant No. NU38OT000286; Centers for
262 Disease Control and Prevention Grant No. U18DP006500; and Centers for Disease Control and
263 Prevention Cooperative Agreement Nos. NU58IP000004 and 1U01TR002997-01A1.

264 **REFERENCES**

- 265 1 Baker J, Brovman EY, Rao N, *et al.* Potential Opioid-Related Adverse Drug Events Are Associated
266 With Decreased Revenue in Hip Replacement Surgery in the Older Population. *Geriatr Orthop Surg*
267 *Rehabil.* 2020;11:2151459320915328. doi: 10.1177/2151459320915328
- 268 2 Hospital harm - opioid-related adverse events. <https://ecqi.healthit.gov/ecqm/eh/2024/cms0819v2>
269 (accessed 5 May 2024)
- 270 3 Dasgupta N, Beletsky L, Ciccarone D. Opioid Crisis: No Easy Fix to Its Social and Economic
271 Determinants. *Am J Public Health.* 2018;108:182–6. doi: 10.2105/AJPH.2017.304187
- 272 4 2019 NSDUH annual national report. [https://www.samhsa.gov/data/report/2019-nsduh-annual-](https://www.samhsa.gov/data/report/2019-nsduh-annual-national-report)
273 [national-report](https://www.samhsa.gov/data/report/2019-nsduh-annual-national-report) (accessed 5 May 2024)
- 274 5 Seth P, Rudd RA, Noonan RK, *et al.* Quantifying the Epidemic of Prescription Opioid Overdose
275 Deaths. *Am J Public Health.* 2018;108:500–2. doi: 10.2105/AJPH.2017.304265
- 276 6 Fraser M, Plescia M. The Opioid Epidemic’s Prevention Problem. *Am J Public Health.*
277 2019;109:215–7. doi: 10.2105/AJPH.2018.304859
- 278 7 Ordean A, Tubman-Broeren M. Safety and Efficacy of Buprenorphine-Naloxone in Pregnancy: A
279 Systematic Review of the Literature. *Pathophysiology.* 2023;30:27–36. doi:
280 10.3390/pathophysiology30010004
- 281 8 Bodenreider O, Nguyen D, Chiang P, *et al.* The NLM value set authority center. *Stud Health*
282 *Technol Inform.* 2013;192:1224.
- 283 9 Mandl KD, Gottlieb D, Mandel JC, *et al.* Push Button Population Health: The SMART/HL7 FHIR
284 Bulk Data Access Application Programming Interface. *NPJ Digit Med.* 2020;3:151. doi:
285 10.1038/s41746-020-00358-4

- 286 10 McMurry AJ, Gottlieb DI, Miller TA, *et al.* Cumulus: a federated electronic health record-based
287 learning system powered by Fast Healthcare Interoperability Resources and artificial intelligence. *J*
288 *Am Med Inform Assoc.* 2024;31:1638–47. doi: 10.1093/jamia/ocae130
- 289 11 United States core data for interoperability (USCDI). [https://www.healthit.gov/isa/united-states-core-](https://www.healthit.gov/isa/united-states-core-data-interoperability-uscdi)
290 [data-interoperability-uscdi](https://www.healthit.gov/isa/united-states-core-data-interoperability-uscdi) (accessed 25 October 2023)
- 291 12 Palumbo SA, Adamson KM, Krishnamurthy S, *et al.* Assessment of Probable Opioid Use Disorder
292 Using Electronic Health Record Documentation. *JAMA Netw Open.* 2020;3:e2015909. doi:
293 10.1001/jamanetworkopen.2020.15909
- 294 13 Poulsen MN, Nordberg CM, Troiani V, *et al.* Identification of opioid use disorder using electronic
295 health records: Beyond diagnostic codes. *Drug Alcohol Depend.* 2023;251:110950. doi:
296 10.1016/j.drugalcdep.2023.110950
- 297 14 Parrish F, Do N, Bouhaddou O, *et al.* Implementation of RxNorm as a terminology mediation
298 standard for exchanging pharmacy medication between federal agencies. *AMIA Annu Symp Proc.*
299 2006;1057.
- 300 15 Nelson SJ, Zeng K, Kilbourne J, *et al.* Normalized names for clinical drugs: RxNorm at 6 years. *J*
301 *Am Med Inform Assoc.* 2011;18:441–8. doi: 10.1136/amiajnl-2011-000116
- 302 16 Le H, Chen R, Harris S, *et al.* RxNorm for drug name normalization: a case study of prescription
303 opioids in the FDA adverse events reporting system. *Front Bioinform.* 2023;3:1328613. doi:
304 10.3389/fbinf.2023.1328613
- 305 17 Bodenreider O. The Unified Medical Language System (UMLS): integrating biomedical
306 terminology. *Nucleic Acids Res.* 2004;32:D267–70. doi: 10.1093/nar/gkh061
- 307 18 *Metathesaurus.* National Library of Medicine (US) 2021.

- 308 19 Office of the National Coordinator of Health Information Technology. 21st Century Cures Act Final
309 Rule. 2020. <https://www.healthit.gov/curesrule/resources/information-blocking-faqs> (accessed 12
310 February 2023)
- 311 20 Cumulus Opioid Valueset (Code). GitHub Code. [https://github.com/smart-on-fhir/cumulus-library-](https://github.com/smart-on-fhir/cumulus-library-opioid-valueset)
312 [opioid-valueset](https://github.com/smart-on-fhir/cumulus-library-opioid-valueset) (accessed 10 October 2024)
- 313 21 Cumulus Opioid Valueset (data supplement). [https://github.com/smart-on-fhir/cumulus-library-](https://github.com/smart-on-fhir/cumulus-library-opioid-valueset-supplement)
314 [opioid-valueset-supplement](https://github.com/smart-on-fhir/cumulus-library-opioid-valueset-supplement) (accessed 11 October 2024)
- 315 22 Cumulus Author. Opioids [value set]. VSAC; Published by Cumulus Steward. Updated February
316 2024. Accessed October 28, 2024.
317 <https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1284.1/definition>
- 318 23 CancerLinQ. Opioids. Value Set Authority Center. 2024.
319 <https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1116.449/expansion> (accessed 31 July
320 2024)
- 321 24 IMPAQ International. All Opioids. Value Set Authority Center. 2019.
322 <https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1196.87/expansion> (accessed 31 July 2024)
- 323 25 American College of Emergency Physicians/AMA-PCPI. Opioid Meds. Value Set Authority Center.
324 2020. <https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1106.68/expansion> (accessed 31 July
325 2024)
- 326 26 Agency for Healthcare Research and Quality Clinical Decision Support Connect Project. Opioid pain
327 medications. Value Set Authority Center. 2023.
328 <https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1032.34/expansion> (accessed 31 July 2024)
- 329 27 ECRI. All prescribable opioids used for pain control including Inactive Medications. Value Set

- 330 Authority Center. 2015.
- 331 <https://vsac.nlm.nih.gov/valueset/1.3.6.1.4.1.6997.4.1.2.234.999.3.2/expansion> (accessed 31 July
- 332 2024)
- 333 28 Lantana. Schedule II, III and IV Opioid Medications. Value Set Authority Center. 2024.
- 334 <https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1046.241/expansion> (accessed 31 July
- 335 2024)
- 336 29 Mathematica. Opioid Medications. Value Set Authority Center. 2020.
- 337 <https://vsac.nlm.nih.gov/valueset/2.16.840.1.113883.3.3157.1004.26/expansion> (accessed 31 July
- 338 2024)
- 339 30 Cliniwiz. Opioid medication key words. Value Set Authority Center.
- 340 <https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1200.163/expansion/> (accessed 11 October
- 341 2024)
- 342 31 Noy NF, Shah NH, Whetzel PL, *et al.* BioPortal: ontologies and integrated data resources at the click
- 343 of a mouse. *Nucleic Acids Res.* 2009;37:W170–3. doi: 10.1093/nar/gkp440
- 344 32 National Library of Medicine. MED-RT (Medication Reference Terminology). 2018.
- 345 <https://www.nlm.nih.gov/research/umls/sourcereleasedocs/current/MED-RT/index.html> (accessed 6
- 346 May 2024)
- 347 33 Palchuk MB, Klumpenaar M, Jatkar T, *et al.* Enabling Hierarchical View of RxNorm with NDF-RT
- 348 Drug Classes. *AMIA Annu Symp Proc.* 2010;2010:577–81.
- 349 34 Pathak J, Murphy SP, Willaert BN, *et al.* Using RxNorm and NDF-RT to classify medication data
- 350 extracted from electronic health records: experiences from the Rochester Epidemiology Project.
- 351 *AMIA Annu Symp Proc.* 2011;2011:1089–98.

- 352 35 National Drug File - Reference Terminology - Opioid Receptor Interactions [MoA] - Classes.
353 <http://purl.bioontology.org/ontology/NDFRT/N0000000200> (accessed 14 August 2024)
- 354 36 Dhaliwal A, Gupta M. *Physiology, Opioid Receptor*. StatPearls Publishing 2023.
- 355 37 CancerLinQ. Non Opioid Analgesics. Value Set Authority Center. 2024.
356 <https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1260.173/expansion>
- 357 38 MD Partners. Non opioid pain medications. Value Set Authority Center. 2020.
358 <https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1021.73/expansion> (accessed 16 October
359 2024)
- 360 39 MITRE. Non Opioid from ATC. Value Set Authority Center. 2023.
361 <https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1032.291/expansion> (accessed 16 October
362 2024)
- 363 40 Appendix 1 - RxNorm Relationships (RELA). Published Online First: 1 September 2023.
- 364 41 Toll L, Bruchas MR, Calo' G, *et al.* Nociceptin/orphanin FQ receptor structure, signaling, ligands,
365 functions, and interactions with opioid systems. *Pharmacol Rev.* 2016;68:419–57. doi:
366 10.1124/pr.114.009209
- 367 42 Brigham and Women's Hospital. Opioid (Oral Tablets and Patches only). Value Set Authority
368 Center. 2019. <https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1206.12/expansion> (accessed
369 16 October 2024)
- 370 43 Gov H. USCDI Patient demographics/information. United States Core Data for Interoperability
371 (USCDI). <https://www.healthit.gov/isa/uscdi-data-class/patient-demographicinformation> (accessed
372 29 March 2023)
- 373 44 HL7.FHIR.US.CORE\Profiles and Extensions - FHIR v4.0.1.

- 374 <https://hl7.org/fhir/us/core/STU4/profiles-and-extensions.html> (accessed 10 October 2024)
- 375 45 HL7.FHIR.US.CORE\US Core MedicationRequest Profile - FHIR v4.0.1.
- 376 <https://hl7.org/fhir/us/core/StructureDefinition-us-core-medicationrequest.html> (accessed 10 October
- 377 2024)
- 378 46 US core condition encounter diagnosis profile - US core implementation guide v7.0.0.
- 379 <https://hl7.org/fhir/us/core/StructureDefinition-us-core-condition-encounter-diagnosis.html> (accessed
- 380 10 October 2024)
- 381 47 US Core Condition Problems and Health Concerns Profile - US Core Implementation Guide v7.0.0.
- 382 <https://hl7.org/fhir/us/core/StructureDefinition-us-core-condition-problems-health-concerns.html>
- 383 (accessed 10 October 2024)
- 384 48 US Core Vital Signs Profile - US Core Implementation Guide v7.0.0.
- 385 <https://hl7.org/fhir/us/core/StructureDefinition-us-core-vital-signs.html> (accessed 10 October 2024)
- 386 49 US Core Laboratory Result Observation Profile - US Core Implementation Guide v7.0.0.
- 387 <https://hl7.org/fhir/us/core/StructureDefinition-us-core-observation-lab.html> (accessed 10 October
- 388 2024)
- 389 50 US Core DiagnosticReport Profile for Laboratory Results Reporting - US Core Implementation
- 390 Guide v7.0.0. <https://hl7.org/fhir/us/core/StructureDefinition-us-core-diagnosticreport-lab.html>
- 391 (accessed 10 October 2024)
- 392 51 US Core Observation Clinical Result Profile - US Core Implementation Guide v7.0.0.
- 393 <https://hl7.org/fhir/us/core/StructureDefinition-us-core-observation-clinical-result.html> (accessed 10
- 394 October 2024)
- 395 52 Clinical Notes - US Core Implementation Guide v7.0.0. <https://hl7.org/fhir/us/core/clinical->

- 396 notes.html (accessed 10 October 2024)
- 397 53 US Core Patient Profile - US Core Implementation Guide v7.0.0.
398 <https://hl7.org/fhir/us/core/StructureDefinition-us-core-patient.html> (accessed 10 October 2024)
- 399 54 US Core Encounter Profile - US Core Implementation Guide v7.0.0.
400 <https://hl7.org/fhir/us/core/StructureDefinition-us-core-encounter.html> (accessed 10 October 2024)
- 401 55 Straub L, Huybrechts KF, Hernandez-Diaz S, *et al.* Chronic prescription opioid use in pregnancy in
402 the United States. *Pharmacoepidemiol Drug Saf.* 2021;30:504–13. doi: 10.1002/pds.5194
- 403 56 Straub L, Huybrechts KF, Hernández-Díaz S, *et al.* Trajectories of Prescription Opioid Utilization
404 During Pregnancy Among Prepregnancy Chronic Users and Risk of Neonatal Opioid Withdrawal
405 Syndrome. *Am J Epidemiol.* 2022;191:208–19. doi: 10.1093/aje/kwab249
- 406 57 Straub L, Bateman BT, Hernández-Díaz S, *et al.* Comparative safety of in utero exposure to
407 buprenorphine combined with naloxone vs buprenorphine alone. *JAMA.* 2024;332:805–16. doi:
408 10.1001/jama.2024.11501
- 409 58 Suarez EA, Huybrechts KF, Straub L, *et al.* Buprenorphine versus Methadone for Opioid Use
410 Disorder in Pregnancy. *N Engl J Med.* 2022;387:2033–44. doi: 10.1056/NEJMoa2203318
- 411 59 Spencer M, Garnett M, Miniño A. Drug overdose deaths in the United States, 2002-2022. National
412 Center for Health Statistics (U.S.) 2023.
- 413 60 CDC. Understanding the Opioid Overdose Epidemic. Overdose Prevention. 2024.
414 <https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html>
415 (accessed 10 October 2024)
- 416 61 HL7 Patient Care Work Group. Drug Misuse. Value Set Authority Center. 2023.
417 <https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1222.707/expansion> (accessed 10 October

418 2024)


419 62 Council of State and Territorial Epidemiologists (CSTE). Opioids, Benzodiazepines, or Barbiturates
420 (Tests by Any Method). Value Set Authority Center. 2024.


421 <https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1146.2293/expansion> (accessed 10 October
422 2024)

423 63 Habibzadeh F, Habibzadeh P, Yadollahie M. The apparent prevalence, the true prevalence. *Biochem*
424 *Med* . 2022;32:020101. doi: 10.11613/BM.2022.020101

425

426





Cumulus Opioids

**True
Positive**

**False
Positive**

**Truth
Conflict**

**False
Negative**

**True
Negative**

VSAC Opioids

VSAC Non-opioid

